"The U.S. Food and Drug Administration today granted accelerated approval to Ibrance (palbociclib) to treat advanced (metastatic) breast cancer.
Breast cancer in women is the second most common type of cancer in the United States. It forms i"...
PERJETA is contraindicated in patients with known hypersensitivity to pertuzumab or to any of its excipients.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 6/12/2015
Additional Perjeta Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find support and advances in treatment.